CCA
AZN icon

Criterion Capital Advisors’s AstraZeneca AZN Stock Holding History

Criterion Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$4.6K Hold
30
– – ﹤0.01% 296
2024
Q3 		$4.6K Hold
30
– – ﹤0.01% 296
2024
Q2 		$4.6K Hold
30
– – ﹤0.01% 296
2024
Q1 		$4K Hold
30
– – ﹤0.01% 293
2023
Q4 		$3.97K Buy
+30
New +$3.9K ﹤0.01% 302

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Criterion Capital Advisors's AZN Position: Q4 2024 in Review

Criterion Capital Advisors held its AstraZeneca (AZN) position steady in Q4 2024 at 30 shares worth $4.6K. The position accounts for ﹤0.01% of the portfolio, ranked #296.

Criterion Capital Advisors first reported a position in AZN in Q4 2023 and has held it in 5 quarters since. 1,218 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

  • Criterion Capital Advisors held 30 shares of AstraZeneca worth $4.6K as of Q4 2024.
  • Criterion Capital Advisors left its AstraZeneca share count unchanged in Q4 2024.
  • AstraZeneca made up ﹤0.01% of Criterion Capital Advisors's portfolio in Q4 2024, its #296 holding.
  • Criterion Capital Advisors first reported a position in AstraZeneca in Q4 2023 and has held it in 5 quarters since.
  • 1,218 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on Criterion Capital Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.